Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Immunology/Inflammation related
    (2)
  • Apoptosis
    (1)
TargetMol | Tags By Application
  • ELISA
    (2)
  • Functional assay
    (2)
  • FACS
    (1)
  • FCM
    (1)
TargetMol | Tags By ResearchField
  • Cancer
    (1)
  • Inflammation
    (1)
Filter
Search Result
Results for "

tafasitamab

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    2
    TargetMol | All_Pathways
  • Inhibitory Antibodies
    2
    TargetMol | Inhibitory_Antibodies
Tafasitamab
XmAb5574, Tafasitamab-cxix, MOR00208
T771351422527-84-1
Tafasitamab (XmAb5574) is an FC-modified humanized monoclonal antibody targeting the human B-cell surface antigen CD19 for the study of diffuse large B-cell lymphoma.
  • $239
In Stock
Size
QTY
Anti-CD19 Antibody
T9901A-1348
Anti-CD19 Antibody (Tafasitamab) is an Fc-engineered humanized monoclonal antibody that specifically targets the CD19 antigen on B lymphocytes. The compound mediates potent antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) by enhanced binding to Fcgamma receptors on effector cells, thereby directly inducing cell death and depleting malignant B cells. It serves as a pharmacological tool for investigating diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies.
    Inquiry